Patent IL-160204-A0 (IL)
Title: Diamine derivatives
IPC: C07D417/12
Filed: 2002-08-08
Abstract: 3-9C Carbocyclyl or 5-11-membered heterocyclyl diamine compounds with (carbocyclyl or heterocyclyl)-type substituted on one amino and (aryl or heteroaryl)-type substituent on the other amino, and their salts, solvates and N-oxides are new. 3-9C Carbocyclyl or 5-11-membered heterocyclyl diamine compounds of with formula Q 1>-Q 2>-T 0>-N(R 1>)-Q 3>-N(R 2>)-T 1>-Q 4> (I) and their salts, solvates and N-oxides are new. [Image] R 1>, R 2>H, OH, alkyl or alkoxy; Q 1>5-6C carbocyclyl or 5-7-membered heterocyclyl, or bicyclic or tricyclic condensed carbocyclyl or heterocyclyl, all optionally unsaturated and/or substituted; Q 2>bond or as for Q 1>; Q 3>a group of formula (a); Q 5>1-8C alkylene, 2-8C alkenylene or (CH 2) m-CH 2-A-CH 2-(CH 2) m; A : O, N, S, SO, SO 2, NH, ONH, NHNH, SNH, SONH, or SO 2NH; R 3>, R 4>(on the C, N, S of Q 5> and are on the C, N, S of Q 5>) H, OH, alkyl, alkenyl, alkynyl, halo, haloalkyl, CN, cyanoalkyl, amino, aminoalkyl, optionally substituted acylamino, alkoxyimino, hydroxyimino, acylaminoalkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, COOH, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, carboxyalkylamino, alkoxycarbonylamino, alkoxycarbonylaminoalkyl, carbamoyl, N-mono- or N,N-di-(optionally substituted alkyl)carbamoyl, N-alkenylcarbamoyl, N-alkenylcarbamoylalkyl, N-alkenyl-N-alkyl-carbamoyl, N-alkenyl-N-alkyl-carbamoylalkyl, N-alkoxycarbamoyl, N-alkoxycarbamoylalkyl, N-alkyl-N-alkoxy-carbamoyl, N-alkyl-N-alkoxy-carbamoylalkyl, carbazoyl (optionally substituted by 1-3 alkyl), alkylsulfonyl, alkylsulfonylalkyl, optionally substituted 3-6-membered heterocyclylcarbonyl, carbamoylalkyl, N-alkyl- or N,N-dialkyl-carbamoylalkyl (optionally substituted), carbamoyloxyalkyl, N-alkyl- or N,N-dialkyl-carbamoyloxyalkyl, optionally substituted 3-6-membered heterocyclylcarbonyloxyalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkylsulfonylamino, arylsulfonylamino, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylsulfonylaminocarbonyl, arylsulfonylaminocarbonyl, alkylsulfonylaminocarbonylalkyl, arylsulfonylaminocarbonylalkyl, oxo, carbamoyloxy, aralkyloxy, carboxyalkyloxy, acyloxy, acyloxyalkyl, arylsulfonyl, alkoxycarbonylalkylsulfonyl, carboxyalkylsulfonyl, alkoxycarbonylacyl, alkoxyalkyloxycarbonyl, alkoxyacyl, hydroxyacyl, haloacyl, carboxyacyl, aminoacyl, acyloxyacyl, acyloxyalkylsulfonyl, hydroxyalkylsulfonyl, alkoxyalkylsulfonyl, optionally substituted 3-6-membered heterocyclylsulfonyl, N,N-dialkyl-carbamoylacyl (optionally substituted in the alkyl), N, N-dialkyl-carbamoylacyl (optionally substituted in the alkyl), aminoacyl, N,N-dialkyl-carbamoylacyl (optionally substituted in the alkyl), N,N-dialkyl-carbamoylalkylsulfonyl (optionally substituted in the alkyl), alkylsulfonylacyl, aminocarbothioyl, N,N-dialkyl-carbothioyl or alkoxyalkyl(thiocarbonyl); or R 3>+R 4>1-5C alkylene, 2-5C alkenylene, 1-5C alkylenedioxy or carbonyldioxy; Q 4>aryl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkenyl, or optionally unsaturated bicyclic or tricyclic fused carbocycle or heterocycle (all optionally substituted); T 0>carbonyl or thiocarbonyl; T 1>carbonyl, sulfonyl, CO-CO-NR', CS-CO-NR', CO-CS-NR', CS-CS-NR', CO-A 1>-NR, CO-CO-NR', CO-NH, CS-NH, CO-NH-NH, CO-A 2>-CO, CO-A 3>-CO-NH, CO-C(N=ORa)-NRb, CS-C(N=ORa)-NRb, CO-N=N, CS-N=N, C(=NORc)-CO-NRd, C(=N-NReRf)-CO-NRg or thiocarbonyl; R' : H, alkyl or alkoxy; A 1>optionally substituted 1-5C alkylene; R : H, OH, alkyl or alkoxy; A 2>bond or 1-5C alkylene; A 3>1-5C alkylene; Ra : H, alkyl or alkanoyl; Rb, Rd, Rg : H, OH, alkyl or alkoxy; Rc : H, alkyl, alkanoyl, aryl or aralkyl; Re, Rf : H, alkyl, alkanoyl, alkyl(thiocarbonyl). Independent claims are also included for compounds of formula NH(R 1>)-Q 3>-N(R 2>)-T 1>-Q 4> (IV) and Q'-Q 2>-CO-N(R 1>)-Q 3>-NH(R 2>) (9). Q 4> 1>aryl, heteroaryl, or optionally unsaturated bicyclic or tricyclic fused carbocycle or heterocycle (all optionally substituted); Q' : optionally unsaturated bicyclic or tricyclic fused heterocycle (optionally substituted). ACTIVITY : Cardiant; Thrombolytic; Antiinflammatory; Anticoagulant. N 1>-(4-Chlorophenyl)-N 2>-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl)carbonyl]amino}cyclohexyl)ethane diamide hydrochloride inhibited human FXa with IC 5 0 1.2 nM. MECHANISM OF ACTION : Activated plasma coagulation factor X inhibitor.